FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
6/28/2022 9:59:44 PM | Chg. -0.050 | Volume | Bid9:59:44 PM | Ask9:59:44 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
28.850EUR | -0.17% | 40,317 Turnover: 1.17 mill. |
28.800Bid Size: 3,000 | 28.960Ask Size: 420 | 16.17 bill.EUR | 3.18% | 8.88 |
GlobeNewswire
6/11/2021
UPDATE -- Humacyte Expands Strategic Global Partnership with Fresenius Medical Care
GlobeNewswire
11/11/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...
GlobeNewswire
11/4/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...
GlobeNewswire
10/29/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fresenius Medica...
GlobeNewswire
10/23/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medic...
GlobeNewswire
6/9/2017
KISSEI TO MARKET AVACOPAN IN JAPAN FOR VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
GlobeNewswire
1/27/2011
Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab®